Merck & Co. has ended clinical development of nemtabrutinib after stopping a trio of phase 3 blood cancer trials. The decision followed a review of Bellwave-011 in which an external data monitoring committee suggested the BTK inhibitor’s risks may outweigh its benefits.

After confirming that conclusion, Merck discontinued the wider phase 3 Bellwave program, including Bellwave-008 and Bellwave-010. The studies were testing nemtabrutinib, also called ARQ 531 and MK-1026, as a monotherapy and in combination in various populations of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The road here

The setback closes out a program tied to Merck’s $2.7 billion takeover of ArQule in 2019. At the time, nemtabrutinib had generated durable responses in patients with B-cell malignancies in an early-phase trial, and Merck paid a more than 100% premium to acquire the company.

That acquisition also put Merck into a competitive race with Eli Lilly, which bought a rival BTK inhibitor through its $8 billion takeover of Loxo Oncology. Lilly went on to win FDA approval for Jaypirca in 2023 and expanded into CLL and SLL in 2025.

The strategic read

Merck’s write-down history had already signaled that confidence in nemtabrutinib was deteriorating before this week’s termination. When Merck bought ArQule, it valued the acquired R&D project at $2.3 billion. It cut $275 million from that figure in 2021 because of changes in expected development costs and a delay to the anticipated launch, then recorded a $1.7 billion charge in 2022 after talks with regulatory agencies showed development would take longer than expected. Following those revisions, the company carried a $418 million valuation for the project through its latest annual report.

The commercial implication is straightforward: Merck is exiting a late-stage attempt in a large blood cancer market after years of shrinking internal expectations, while a direct rival has already established regulatory and market position. For business development strategy, it is another reminder that a large acquisition premium and encouraging early data do not protect an oncology asset once late-stage benefit-risk turns against it.